Milger, Katrin and Suhling, Hendrik and Skowasch, Dirk and Holtdirk, Annette and Kneidinger, Nikolaus and Behr, Jurgen and Timmermann, Hartmut and Schulz, Christian and Schmidt, Olaf and Ehmann, Rainer and Hamelmann, Eckard and Idzko, Marco and Taube, Christian and Lommatzsch, Marek and Buhl, Roland and Korn, Stephanie (2023) Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 11 (9). ISSN 2213-2198, 2213-2201
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: Recently, criteria for evaluation of response to biologics have been proposed and the concept of clinical remission has gained attention as a possible goal even in severe asthma. OBJECTIVE: To analyze the response and remission in the German Asthma Net severe asthma registry cohort. METHODS: We included adults not using a biologic at baseline (V0) and compared patients treated between V0 and 1-year visit (V1) without using a biologic (group A) to patients starting with a biologic after V0 and continuing it up to V1 (group B). We applied the Biologics Asthma Response Score to quantify composite response in good, intermediate, or insufficient. We defined clinical remission (R) as absence of significant symptoms (Asthma Control Test score & DDAG; 20 at V1) in the absence of exacerbations and oral corticosteroid therapy. RESULTS: Group A included 233 and group B 210 patients, the latter receiving omalizumab (n = 33), mepolizumab (n = 40), benralizumab (n = 81), reslizumab (n = 1), or dupilumab (n = 56). At baseline, group B had less often an allergic phenotype (35.2% vs 41.6%), lower Asthma Control Test score (median, 12 vs 14), more exacerbations in the past year (median, 3 vs 2), and more often high-dose inhaled corticosteroid treatment (71.4% vs 51.5%) than group A. After 1 year of treatment, rates of response (good: 61.4% vs 34.8%; intermediate: 26.7% vs 42.9%; insufficient: 11.9% vs. 22.3%) and/or clinical remission (37.6% vs 17.2%) were higher in group B than in group A. CONCLUSIONS: Despite more severe asthma at baseline, patients treated with biologics had a markedly higher probability of achieving good clinical response and/or remission than patients treated without biologics. & COPY; 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). (J Allergy Clin Immunol Pract 2023;11:2701-12)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MONOCLONAL-ANTIBODY; EOSINOPHILIC ASTHMA; MEPOLIZUMAB; BENRALIZUMAB; Severe asthma; Treatment; Biologic; Response; Remission; Exacerbations; OCS use; Asthma control; Pulmonary function |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 12:46 |
| Last Modified: | 30 Jan 2024 12:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60700 |
Actions (login required)
 |
View Item |
